Citi analyst Yigal Nochomovitz raised the firm’s price target on Apellis (APLS) to $46 from $41 and keeps a Buy rating on the shares after Empaveli received FDA label expansion approval to be the first treatment for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in patients over 12 years old. Citi believes Empaveli’s “best-in-class” profile should bring momentum back to the Apellis story.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Buy Rating Driven by Empaveli’s Market Potential and Strong Growth Prospects
- Apellis Pharmaceuticals Receives Buy Rating Following Empaveli’s FDA Approval and Market Potential
- FDA approves Apellis’ Empaveli for treatment of C3 glomerulopathy
- Apellis Pharmaceuticals trading halted, news pending
- Apellis price target raised to $50 from $47 at Baird